Resource Library

Whether or not someone continues GLP-1 therapy is a clinical decision that should be made in partnership with their healthcare provider. But what are the strategic benefits, and what are the risks?

MASH isn’t a new problem, it’s a newly visible one. As obesity and diabetes continue to drive healthcare costs, metabolic liver disease is emerging as a critical missing piece in many employer strategies.

Watch the on-demand webinar that takes a deep dive into how organizations can respond to GLP-1 demand even when the medications aren’t covered on their formulary.

Watch the on-demand webinar that takes a deep dive into how new pricing for GLP-1s is reshaping access and raising questions about how to design sustainable benefits.

For too long, culture has framed this transition as the beginning of invisibility or loss. In reality, it’s an opportunity to take up space, rebuild strength, and redefine what thriving looks like in midlife. It’s just a matter of knowing how.

Plan sponsors don’t just need to save money today; they need to ensure that those savings don’t backfire tomorrow in the form of worse outcomes and higher costs.

At Vida, we know our medical team is at the heart of everything we do. In this new series, we’re spotlighting the physicians, dietitians, and coaches who bring their expertise and compassion to every member interaction. Each profile highlights their unique journeys, the impact they’ve made helping members manage chronic conditions, and the knowledge they bring to advancing evidence-based care.

Watch the on-demand webinar exploring how obesity care is transforming cardiac outcomes, and what it means for employers, health plans, and clinicians.

Though it can be entertaining, it’s confusing. And if you’re trying to figure out what actually works, it’s exhausting.

Across telecommunications, manufacturing, and financial services, employers are turning to Vida to address the dual challenge of rising GLP-1 costs and complex cardiometabolic conditions. This case study highlights three self-insured employers that partnered with Vida to tailor obesity care for their populations—with remarkable results:

Vida’s programs reduce medical and pharmacy costs within the first year. Here’s what organizations
can expect when obesity and diabetes are treated together through clinical, coordinated care.

Let’s recognize what’s really going on when we cope with comfort food.